Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07629583
PHASE1

To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis

Sponsor: Genentech, Inc.

View on ClinicalTrials.gov

Summary

The study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cevostamab in participants with systemic lupus erythematosus (SLE) with or without active lupus nephritis (LN).

Official title: An Open-Label, Multicenter, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cevostamab in Patients With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

46

Start Date

2026-11-02

Completion Date

2030-03-29

Last Updated

2026-11-05

Healthy Volunteers

No

Interventions

DRUG

Cevostamab

Participants will receive cevostamab IV as per the schedule given in the protocol.

DRUG

Tocilizumab

Tocilizumab may be used as rescue medication for participants who experience a cytokine release syndrome (CRS) event.

Locations (11)

Royal Melbourne Hospital

Parkville, Victoria, Australia

Hospital Moinhos de Vento

Porto Alegre, Rio Grande do Sul, Brazil

Hospital de Clnicas de Porto Alegre

Porto Alegre, Rio Grande do Sul, Brazil

Hospital das Clínicas FMRP-USP

Ribeirão Preto, São Paulo, Brazil

Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto

Sao Jose Rio Preto, São Paulo, Brazil

Peking University First Hospital

Beijing, Beijing Municipality, China

Peking University People's Hospital

Beijing, Beijing Municipality, China

Pingxiang People's Hospital

Pingxiang, Jiangxi, China

Hopital Rangueil

Toulouse, Haute Garonne, France

Istituto Clinico Humanitas

Rozzano, Lombardy, Italy

Hospital Universitario Virgen Macarena

Seville, Spain